GUCY2C molecular staging personalizes colorectal cancer patient management

Biomarkers in Medicine

Volumn 6, Issue 3, 2012, Pages 339-348

  Gong, Jian P ^a,b   Schulz, Stephanie ^a   Hyslop, Terry ^a   Waldman, Scott A ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

biomarker; colorectal cancer; guanylyl cyclase C; occult tumor burden; prediction; prognosis; quantitative reverse transcriptase PCR; racial disparities; staging

Indexed keywords

BIOLOGICAL MARKER; PROTEIN GUCY2C; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; COLORECTAL CANCER; COLORECTAL SURGERY; HISTOPATHOLOGY; HUMAN; LYMPH NODE METASTASIS; PERSONALIZED MEDICINE; PROTEIN FUNCTION; RACE DIFFERENCE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; TUMOR CELL; TUMOR VOLUME;

COLORECTAL NEOPLASMS; HUMANS; INDIVIDUALIZED MEDICINE; NEOPLASM STAGING; RECEPTORS, GUANYLATE CYCLASE-COUPLED; RECEPTORS, PEPTIDE; TUMOR MARKERS, BIOLOGICAL;

EID: 84862899607     PISSN: 17520363     EISSN: 17520371     Source Type: Journal    
DOI: 10.2217/bmm.12.24     Document Type: Review

References (121)

1. Iddings D, Ahmad A, Elashoff D, Bilchik A. The prognostic effect of micrometastases in previously staged lymph node negative (N0) colorectal carcinoma: a meta-analysis. Ann. Surg. Oncol. 13(11), 1386-1392 (2006).
2. Mejia A, Waldman S. Previstage™ GCC test for staging patients with colorectal cancer. Expert Rev. Mol. Diag. 8, 571-578 (2008).
3. Mejia A, Schulz S, Hyslop T, Weinberg DS, Waldman SA. GUCY2C reverse transcriptase PCR to stage pN0 colorectal cancer patients. Expert Rev. Mol. Diagn. 9(8), 777-785 (2009).
4. Nicastri DG, Doucette JT, Godfrey TE, Hughes SJ. Is occult lymph node disease in colorectal cancer patients clinically significant? A review of the relevant literature. J. Mol. Diagn. 9(5), 563-571 (2007).
5. Clarke SJ, Chua W, Moore M et al. Use of inflammatory markers to guide cancer treatment. Clin. Pharmacol. Ther. 90(3), 475-478 (2011).
6. Nass SJ, Balogh E. National Cancer Policy Summit: addressing opportunities and challenges in cancer care and research. Clin. Pharmacol. Ther. 89(6), 770-771 (2011).
7. Paugh SW, Stocco G, Mccorkle JR, Diouf B, Crews KR, Evans WE. Cancer pharmacogenomics. Clin. Pharmacol. Ther. 90(3), 461-466 (2011).
8. Zahedi P, De Souza R, Piquette-Miller M. Optimizing cancer care: is the future bright? Clin. Pharmacol. Ther. 90(3), 347-350 (2011).
9. Amstutz U, Carleton BC. Pharmacogenetic testing: time for clinical practice guidelines. Clin. Pharmacol. Ther. 89(6), 924-927 (2011).
10. Haga SB, Burke W. Practical ethics: establishing a pathway to benefit for complex pharmacogenomic tests. Clin. Pharmacol. Ther. 90(1), 25-27 (2011).
11. Waldman SA, Hohl RJ, Kearns GL, Swan SJ, Terzic A. Clinical pharmacology as a foundation for translational science. Clin. Pharmacol. Ther. 90(1), 10-13 (2011).
12. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J. Clin. 57(1), 43-66 (2007).
13. Compton CC, Greene FL. The staging of colorectal cancer: 2004 and beyond. CA Cancer J. Clin. 54(6), 295-308 (2004).
14. Greene FL. AJCC Cancer Staging Manual (6th Edition). Springer, NY, USA (2002).
15. Meyerhardt JA, Mayer RJ. Systemic therapy for colorectal cancer. N. Engl. J. Med. 352(5), 476-487 (2005).
16. Ries LA, Wingo PA, Miller DS et al. The annual report to the nation on the status of cancer, 1973-1997, with a special section on colorectal cancer. Cancer 88(10), 2398-2424 (2000).
17. Sobrero A, Kerr D, Glimelius B et al. New directions in the treatment of colorectal cancer: a look to the future. Eur. J. Cancer 36(5), 559-566 (2000).
18. Wolpin BM, Meyerhardt JA, Mamon HJ, Mayer RJ. Adjuvant treatment of colorectal cancer. CA Cancer J. Clin. 57(3), 168-185 (2007).
19. Andre T, Boni C, Mounedji-Boudiaf L et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N. Engl. J. Med. 350(23), 2343-2351 (2004).
20. Bilchik AJ, Hoon DS, Saha S et al. Prognostic impact of micrometastases in colon cancer: interim results of a prospective multicenter trial. Ann. Surg. 246(4), 568-575; discussion 575-567 (2007).
21. Mamounas E, Wieand S, Wolmark N et al. Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four national surgical adjuvant breast and bowel project adjuvant studies (C-01, C-02, C-03, and C-04). J. Clin. Oncol. 17(5), 1349-1355 (1999).
22. Quasar Collaborative Group, Gray R, Barnwell J et al. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet 370(9604), 2020-2029 (2007).
23. Iddings D, Bilchik A The biologic significance of micrometastatic disease and sentinel lymph node technology on colorectal cancer. J. Surg. Oncol. 96(8), 671-677 (2007).
24. Ratto C, Sofo L, Ippoliti M et al. Accurate lymph-node detection in colorectal specimens resected for cancer is of prognostic significance. Dis. Colon Rectum 42(2), 143-154; discussion 154-148 (1999).
25. Galandiuk S, Wieand HS, Moertel CG et al. Patterns of recurrence after curative resection of carcinoma of the colon and rectum. Surg. Gynecol. Obstet. 174(1), 27-32 (1992).
26. Greenson JK, Isenhart CE, Rice R, Mojzisik C, Houchens D, Martin EW Jr. Identification of occult micrometastases in pericolic lymph nodes of Duke's B colorectal cancer patients using monoclonal antibodies against cytokeratin and CC49. Correlation with long-term survival. Cancer 73(3), 563-569 (1994).
27. Liefers GJ, Cleton-Jansen AM, van de Velde CJ et al. Micrometastases and survival in stage II colorectal cancer. N. Engl. J. Med. 339(4), 223-228 (1998).
28. Andre T, Sargent D, Tabernero J et al. Current issues in adjuvant treatment of stage II colon cancer. Ann. Surg. Oncol. 13(6), 887-898 (2006).
29. De Gramont A, Tournigand C, Andre T, Larsen AK, Louvet C. Targeted agents for adjuvant therapy of colon cancer. Semin. Oncol. 33(6 Suppl. 11), S42-S45 (2006).
30. De Gramont A, Tournigand C, Andre T, Larsen AK, Louvet C. Adjuvant therapy for stage II and III colorectal cancer. Semin. Oncol. 34(2 Suppl. 1), S37-S40 (2007).
31. Fuchs CS, Mayer RJ. Adjuvant chemotherapy for colon and rectal cancer. Semin. Oncol. 22(5), 472-487 (1995).
32. Krook JE, Moertel CG, Gunderson LL et al. Effective surgical adjuvant therapy for high-risk rectal carcinoma. N. Engl. J. Med. 324(11), 709-715 (1991).
33. Moertel CG, Fleming TR, Macdonald JS et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N. Engl. J. Med. 322(6), 352-358 (1990).
34. Wolmark N, Rockette H, Fisher B et al. The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from national surgical adjuvant breast and bowel project protocol C-03. J. Clin. Oncol. 11(10), 1879-1887 (1993).
35. Kopetz S, Chang GJ, Overman MJ et al. improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J. Clin. Oncol. 27(22), 3677-3683 (2009).
36. Sargent D, Sobrero A, Grothey A et al. Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials. J. Clin. Oncol. 27(6), 872-877 (2009).
37. Benson AB 3rd, Schrag D, Somerfield MR et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J. Clin. Oncol. 22(16), 3408-3419 (2004).
38. Figueredo A, Charette ML, Maroun J, Brouwers MC, Zuraw L. Adjuvant therapy for stage II colon cancer: a systematic review from the cancer care ontario program in evidence-based care's gastrointestinal cancer disease site group. J. Clin. Oncol. 22(16), 3395-3407 (2004).
39. Winn R, McClure J. The NCCN clinical practice guidelines in oncology. J. Natl Compr. Canc. Netw. 1(9), 5-13 (2003).
40. Frick GS, Pitari GM, Weinberg DS, Hyslop T, Schulz S, Waldman SA. Guanylyl cyclase C: a molecular marker for staging and postoperative surveillance of patients with colorectal cancer. Expert Rev. Mol. Diagn. 5(5), 701-713 (2005).
41. Gelmann A, Desnoyers R, Cagir B, Weinberg D, Boman BM, Waldman SA. Colorectal cancer staging and adjuvant chemotherapy. Expert Opin. Pharmacother. 1(4), 737-755 (2000).
42. Waldman SA, Hyslop T, Schulz S et al. Association of GUCY2C expression in lymph nodes with time to recurrence and disease-free survival in pN0 colorectal cancer. JAMA 301(7), 745-752 (2009).
43. Cagir B, Gelmann A, Park J et al. Guanylyl cyclase C messenger RNA is a biomarker for recurrent stage II colorectal cancer. Ann. Intern. Med. 131(11), 805-812 (1999).
44. Almenoff JS, Williams SI, Scheving LA, Judd AK, Schoolnik GK. Ligand-based histochemical localization and capture of cells expressing heat-stable enterotoxin receptors. Mol. Microbiol. 8(5), 865-873 (1993).
45. Carrithers SL, Barber MT, Biswas S et al. Guanylyl cyclase C is a selective marker for metastatic colorectal tumors in human extraintestinal tissues. Proc. Natl Acad. Sci. USA 93(25), 14827-14832 (1996).
46. Carrithers SL, Parkinson SJ, Goldstein S, Park P, Robertson DC, Waldman SA. Escherichia coli heat-stable toxin receptors in human colonic tumors. Gastroenterology 107(6), 1653-1661 (1994).
47. Cohen MB, Guarino A, Shukla R, Giannella RA. Age-related differences in receptors for Escherichia coli heat-stable enterotoxin in the small and large intestine of children. Gastroenterology 94(2), 367-373 (1988).
48. Cohen MB, Moyer MS, Luttrell M, Giannella RA. The immature rat small intestine exhibits an increased sensitivity and response to Escherichia coli heat-stable enterotoxin. Pediatr. Res. 20(6), 555-560 (1986).
49. Guarino A, Cohen M, Thompson M, Dharmsathaphorn K, Giannella R. T84 cell receptor binding and guanyl cyclase activation by Escherichia coli heat-stable toxin. Am. J. Physiol. 253(6 Pt 1), G775-G780 (1987).
50. Guarino A, Cohen MB, Giannella RA. Small and large intestinal guanylate cyclase activity in children: effect of age and stimulation by Escherichia coli heat-stable enterotoxin. Pediatr. Res. 21(6), 551-555 (1987).
51. Guarino A, Cohen MB, Overmann G, Thompson MR, Giannella RA. Binding of E. coli heat-stable enterotoxin to rat intestinal brush borders and to basolateral membranes. Dig. Dis. Sci. 32(9), 1017-1026 (1987).
52. Lucas KA, Pitari GM, Kazerounian S et al. Guanylyl cyclases and signaling by cyclic GMP. Pharmacol. Rev. 52(3), 375-414 (2000).
53. Rao MC, Guandalini S, Smith PL, Field M. Mode of action of heat-stable Escherichia coli enterotoxin. Tissue and subcellular specificities and role of cyclic GMP. Biochim. Biophys. Acta 632(1), 35-46 (1980).
54. Carrithers SL, Ott CE, Hill MJ et al. Guanylin and uroguanylin induce natriuresis in mice lacking guanylyl cyclase-C receptor. Kidney Int. 65(1), 40-53 (2004).
55. Field M. Mechanisms of action of cholera and Escherichia coli enterotoxins. Am. J. Clin. Nutr. 32(1), 189-196 (1979).
56. Field M, Graf LH Jr, Laird WJ, Smith PL. Heat-stable enterotoxin of Escherichia coli: in vitro effects on guanylate cyclase activity, cyclic GMP concentration, and ion transport in small intestine. Proc. Natl Acad. Sci. USA 75(6), 2800-2804 (1978).
57. Guerrant RL, Hughes JM, Chang B, Robertson DC, Murad F. Activation of intestinal guanylate cyclase by heat-stable enterotoxin of Escherichia coli: studies of tissue specificity, potential receptors, and intermediates. J. Infect. Dis. 142(2), 220-228 (1980).
58. Hughes JM, Murad F, Chang B, Guerrant RL. Role of cyclic GMP in the action of heat-stable enterotoxin of Escherichia coli. Nature 271(5647), 755-756 (1978).
59. Kuno T, Kamisaki Y, Waldman SA, Gariepy J, Schoolnik G, Murad F. Characterization of the receptor for heat-stable enterotoxin from Escherichia coli in rat intestine. J. Biol. Chem. 261(3), 1470-1476 (1986).
60. Schulz S, Green CK, Yuen PS, Garbers DL. Guanylyl cyclase is a heat-stable enterotoxin receptor. Cell 63(5), 941-948 (1990).
61. Li P, Lin JE, Chervoneva I, Schulz S, Waldman SA, Pitari GM. Homeostatic control of the crypt-villus axis by the bacterial enterotoxin receptor guanylyl cyclase C restricts the proliferating compartment in intestine. Am. J. Pathol. 171(6), 1847-1858 (2007).
62. Li P, Lin JE, Snook AE et al. Colorectal cancer as a paracrine deficiency syndrome amenable to oral hormone replacement therapy. Clin. Transl. Sci. 1, 163-167 (2008).
63. Li P, Lin JE, Snook AE, Schulz S, Pitari GM, Waldman SA. Colorectal cancer is a paracrine deficiency syndrome which can be prevented and treated by oral hormone replacement therapy. Curr. Mol. Pharmacol. 2, 285-292 (2008
64. Li P, Schulz S, Bombonati A et al. Guanylyl cyclase C suppresses intestinal tumorigenesis by restricting proliferation and maintaining genomic integrity. Gastroenterology 133(2), 599-607 (2007).
65. Lin JE, Li P, Pitari GM, Schulz S, Waldman SA. Guanylyl cyclase C in colorectal cancer: susceptibility gene and potential therapeutic target. Future Oncol. 5(4), 509-522 (2009).
66. Lin JE, Li P, Snook AE et al. GUCY2C establishes lineage dependence in intestinal tumorigenesis through AKT. Gastroenterology 138, 241-254 (2008).
67. Pitari GM, Baksh RI, Harris DM, Li P, Kazerounian S, Waldman SA. Interruption of homologous desensitization in cyclic guanosine 3',5'-monophosphate signaling restores colon cancer cytostasis by bacterial enterotoxins. Cancer Res. 65(23), 11129-11135 (2005).
68. Pitari GM, Di Guglielmo MD, Park J, Schulz S, Waldman SA. Guanylyl cyclase C agonists regulate progression through the cell cycle of human colon carcinoma cells. Proc. Natl Acad. Sci. USA 98(14), 7846-7851 (2001).
69. Pitari GM, Li P, Lin JE et al. The paracrine hormone hypothesis of colorectal cancer. Clin. Pharmacol. Ther. 82(4), 441-447 (2007).
70. Pitari GM, Lin JE, Shah FJ et al. Enterotoxin preconditioning restores calcium-sensing receptor-mediated cytostasis in colon cancer cells. Carcinogenesis 29, 1601-1607 (2008).
71. Pitari GM, Zingman LV, Hodgson DM et al. Bacterial enterotoxins are associated with resistance to colon cancer. Proc. Natl Acad. Sci. USA 100(5), 2695-2699 (2003).
72. Shailubhai K, Yu HH, Karunanandaa K et al. Uroguanylin treatment suppresses polyp formation in the Apc (Min/+) mouse and induces apoptosis in human colon adenocarcinoma cells via cyclic GMP. Cancer Res. 60(18), 5151-5157 (2000).
73. Steinbrecher KA, Wowk SA, Rudolph JA, Witte DP, Cohen MB. Targeted inactivation of the mouse guanylin gene results in altered dynamics of colonic epithelial proliferation. Am. J. Pathol. 161(6), 2169-2178 (2002).
74. Birkenkamp-Demtroder K, Lotte Christensen L, Harder Olesen S et al. Gene expression in colorectal cancer. Cancer Res. 62, 4352-4363 (2002).
75. Cohen MB, Hawkins JA, Witte DP. Guanylin mRNA expression in human intestine and colorectal adenocarcinoma. Laboratory Invest. 78(1), 101-108 (1998).
76. Notterman DA, Alon U, Sierk AJ, Levine A. Transcriptional gene expression profiles of colorectal adenoma, adenocarcinoma, and normal tissue examined by oligonucleotide arrays. Cancer Res. 61(7), 3124-3130 (2001).
77. Steinbrecher KA, Tuohy TM, Heppner Goss K et al. Expression of guanylin is downregulated in mouse and human intestinal adenomas. Biochem. Biophys. Res. Commun. 273(1), 225-230 (2000).
78. Wilson C, Schulz S, Hyslop T, Waldman SA. Silencing of guanylin and uroguanylin expression in colon cancer. Expert Rev. Mol. Diagn. 9(8), 777-785 (2009).
79. Birbe R, Palazzo JP, Walters R, Weinberg D, Schulz S, Waldman SA. Guanylyl cyclase C is a marker of intestinal metaplasia, dysplasia, and adenocarcinoma of the gastrointestinal tract. Hum. Pathol. 36(2), 170-179 (2005).
80. Fava TA, Desnoyers R, Schulz S et al. Ectopic expression of guanylyl cyclase C in CD34+ progenitor cells in peripheral blood. J. Clin. Oncol. 19(19), 3951-3959 (2001).
81. Waldman SA, Barber M, Pearlman J, Park J, George R, Parkinson SJ. Heterogeneity of guanylyl cyclase C expressed by human colorectal cancer cell lines in vitro. Cancer Epidemiol. Biomarkers Prev. 7(6), 505-514 (1998).
82. Waldman SA, Cagir B, Rakinic J et al. Use of guanylyl cyclase C for detecting micrometastases in lymph nodes of patients with colon cancer. Dis. Colon Rectum 41(3), 310-315 (1998).
83. Schulz S, Hyslop T, Haaf J et al. A validated quantitative assay to detect occult micrometastases by reverse transcriptase-polymerase chain reaction of guanylyl cyclase C in patients with colorectal cancer. Clin. Cancer Res. 12(15), 4545-4552 (2006).
84. Witek ME, Nielsen K, Walters R et al. The putative tumor suppressor Cdx2 is overexpressed by human colorectal adenocarcinomas. Clin. Cancer Res. 11(24 Pt 1), 8549-8556 (2005).
85. Beaulieu M, Desaulniers M, Bertrand N et al. Analytical performance of a qRT-PCR assay to detect guanylyl cyclase C in FFPE lymph nodes of patients with colon cancer. Diagn. Mol. Pathol. 19(1), 20-27 (2010).
86. Haince JF, Houde M, Beaudry G et al. Comparison of histopathology and RT-qPCR amplification of guanylyl cyclase C for detection of colon cancer metastases in lymph nodes. J. Clin. Pathol. 63(6), 530-537 (2010).
87. Sargent DJ, Resnick MB, Meyers MO et al. Evaluation of guanylyl cyclase C lymph node status for colon cancer staging and prognosis. Ann. Surg. Oncol. 18(12), 3261-3270 (2011).
88. Cunningham D, Atkin W, Lenz HJ et al. Colorectal cancer. Lancet 375(9719), 1030-1047 (2010).
89. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC Cancer Staging Manual (7th Edition). Springer, NY, USA, 143-164 (2009).
90. Hyslop T, Weinberg DS, Schulz S, Barkun A, Waldman SA. Occult tumor burden predicts disease recurrence in lymph node-negative colorectal cancer. Clin. Cancer Res. 17(10), 3293-3303 (2011).
91. Polite BN, Dignam JJ, Olopade OI. Colorectal cancer and race: understanding the differences in outcomes between African Americans and whites. Med. Clin. North Am. 89(4), 771-793 (2005).
92. Polite BN, Dignam JJ, Olopade OI. Colorectal cancer model of health disparities: understanding mortality differences in minority populations. J. Clin. Oncol. 24(14), 2179-2187 (2006).
93. Soneji S, Iyer SS, Armstrong K, Asch DA. Racial disparities in stage-specific colorectal cancer mortality: 1960-2005. Am. J. Public Health 100(10), 1912-1916 (2010).
94. Le H, Ziogas A, Lipkin SM, Zell JA. Effects of socioeconomic status and treatment disparities in colorectal cancer survival. Cancer Epidemiol. Biomarkers Prev. 17(8), 1950-1962 (2008).
95. Chien C, Morimoto LM, Tom J, Li CI. Differences in colorectal carcinoma stage and survival by race and ethnicity. Cancer 104(3), 629-639 (2005).
96. Laiyemo AO, Doubeni C, Pinsky PF et al. Race and colorectal cancer disparities: health-care utilization vs different cancer susceptibilities. J. Natl Cancer Inst. 102(8), 538-546 (2010).
97. Marcella S, Miller JE. Racial differences in colorectal cancer mortality. The importance of stage and socioeconomic status. J. Clin. Epidemiol. 54(4), 359-366 (2001).
98. Mayberry RM, Coates RJ, Hill HA et al. Determinants of black/white differences in colon cancer survival. J. Natl Cancer Inst. 87(22), 1686-1693 (1995).
99. White A, Vernon SW, Franzini L, Du XL. Racial disparities in colorectal cancer survival: to what extent are racial disparities explained by differences in treatment, tumor characteristics, or hospital characteristics? Cancer 116(19), 4622-4631 (2010).
100. Chen VW, Fenoglio-Preiser CM, Wu XC et al. Aggressiveness of colon carcinoma in blacks and whites. National Cancer Institute black/white cancer survival study group. Cancer Epidemiol. Biomarkers Prev. 6(12), 1087-1093 (1997).
101. Hyslop T, Weinberg DS, Schulz S, Barkun A, Waldman SA. Occult tumor burden contributes to racial disparities in stage-specific colorectal cancer outcomes. Cancer 118(9), 2532-2540 (2011).
102. Abati A, Liotta LA. Looking forward in diagnostic pathology: the molecular superhighway. Cancer 78(1), 1-3 (1996).
103. Krishna R, Herman G, Wagner JA. Accelerating drug development using biomarkers: a case study with sitagliptin, a novel DPP4 inhibitor for Type 2 diabetes. AAPS J. 10(2), 401-409 (2008).
104. Lee JW, Devanarayan V, Barrett YC et al. Fit-for-purpose method development and validation for successful biomarker measurement. Pharm. Res. 23(2), 312-328 (2006).
105. Lee JW, Weiner RS, Sailstad JM et al. Method validation and measurement of biomarkers in nonclinical and clinical samples in drug development: a conference report. Pharm. Res. 22(4), 499-511 (2005).
106. Wagner JA. Overview of biomarkers and surrogate endpoints in drug development. Dis. Markers 18(2), 41-46 (2002).
107. Wagner JA. Back to the future: driving innovation in drug development. Clin. Pharmacol. Ther. 83(2), 199-202 (2008).
108. Wagner JA. Strategic approach to fit-for-purpose biomarkers in drug development. Annu. Rev. Pharmacol. Toxicol. 48, 631-651 (2008).
109. Wagner JA, Williams SA, Webster CJ. Biomarkers and surrogate end points for fit-for-purpose development and regulatory evaluation of new drugs. Clin. Pharmacol. Ther. 81(1), 104-107 (2007).
110. Williams SA, Slavin DE, Wagner JA, Webster CJ. A cost-effectiveness approach to the qualification and acceptance of biomarkers. Nat. Rev. Drug Discov. 5(11), 897-902 (2006).
111. Park J, Schulz S, Haaf J, Kairys JC, Waldman SA. Ectopic expression of guanylyl cyclase C in adenocarcinomas of the esophagus and stomach. Cancer Epidemiol. Biomarkers Prev. 11(8), 739-744 (2002).
112. Croner RS, Peters A, Brueckl WM et al. Microarray versus conventional prediction of lymph node metastasis in colorectal carcinoma. Cancer 104(2), 395-404 (2005).
113. Frigola J, Song J, Stirzaker C, Hinshelwood RA, Peinado MA, Clark SJ. Epigenetic remodeling in colorectal cancer results in coordinate gene suppression across an entire chromosome band. Nat. Genet. 38(5), 540-549 (2006).
114. Jen J, Kim H, Piantadosi S et al. Allelic loss of chromosome 18q and prognosis in colorectal cancer. N. Engl. J. Med. 331(4), 213-221 (1994).
115. Paik S, Shak S, Tang G et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med. 351(27), 2817-2826 (2004).
116. Wang Y, Jatkoe T, Zhang Y et al. Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer. J. Clin. Oncol. 22(9), 1564-1571 (2004).
117. Sullivan R, Peppercorn J, Sikora K et al. Delivering affordable cancer care in high-income countries. Lancet Oncol. 12(10), 933-980 (2011).
118. Wong WB, Carlson JJ, Thariani R, Veenstra DL. Cost effectiveness of pharmacogenomics: a critical and systematic review. Pharmacoeconomics 28(11), 1001-1013.
119. Allegra CJ, Jessup JM, Somerfield MR et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J. Clin. Oncol. 27(12), 2091-2096 (2009).
120. Wilson C, Schulz S, Waldman S. Cancer biomarkers: where medicine, business, and public policy intersect. Biotechnology Healthcare February, 33-42 (2007).
121. Wilson C, Schulz S, Waldman SA. Biomarker development, commercialization, and regulation: individualization of medicine lost in translation. Clin. Pharmacol. Ther. 81(2), 153-155 (2007).